Drug information of Nimodipine

Mechanism of effect

Nimodipine is a calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle.

Pharmacodynamic

Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers.

Pharmacokinetics

Nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour. The terminal elimination half-life is approximately 8 to 9 hours. Nimodipine is over 95% bound to plasma proteins. Nimodipine is eliminated almost exclusively in the form of metabolites and less than 1% is recovered in the urine as unchanged drug

Drug indications

Migraine Prophylaxis , Ischemic Stroke , Subarachnoid Hemorrhage

Dosage

Usual Adult Dose for Subarachnoid Hemorrhage 60 mg orally every 4 hours Therapy should be started within 96 hours of the event and continued for 21 days.

Drug contraindications

hypersensitivity to drug or its components.

Side effects

nausea , Headache , Tachycardia , rash , Bradycardia , Depression , Diarrhea , Dyspnea , hypotension , acne , edema , abnormal ECG

Interactions

Aluminium MGS , Erythromycin , isosorbide dinitrate , Sodium bicarbonate , Nitroglycerin , Aripiprazole , Aprepitant , Itraconazole , Bosentan , Cimetidine , Voriconazole , Carbamazepine , Ketoconazole , Clarithromycin , Yohimbine , Phentolamine Mesylate , Bicalutamide , Bisoprolol , mitotane , Dolasetron , Indinavir , Idelalisib , Mibefradil , cobicistat , Delavirdine , Aluminium Mg , dicloxacillin , Cefamandole , Apalutamide , Lorlatinib , Troleandomycin , lasmiditan , tecovirimat , tucatinib

Alerts

1- Do not administer nimodipine intravenously or by other parenteral routes. Deaths and serious, life threatening adverse events, including cardiac arrest, cardiovascular collapse, hypotension, and bradycardia, have occurred when the contents of nimodipine capsules have been injected parenterally 2- Blood pressure should be monitored carefully during nimodipine therapy. 3- The metabolism of Nimodipine capsules is decreased in patients with impaired hepatic function. Such patients should have their blood pressure and pulse rate monitored closely and should be given a lower dose 4- Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Points of recommendation

1-Tell your doctor or dentist that you take nimodipine before you receive any medical or dental care, emergency care, or surgery. 2-Nimodipine may cause dizziness or light-headedness. These effects may be worse if you take it with alcohol or certain medicines. Use nimodipine with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it. 3-Your blood pressure and heart rate will need to be monitored while you use nimodipine.

Pregnancy level

C

Related drugs

Mibefradil , Nicardipine , Nisoldipine , Lercanidipine , Nitrendipine